Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Lung Neoplasms × Mass Screening × Clear all

Phase

Status

Completed 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Papillomavirus Infections 1 Neoplasms 1 Multiple Myeloma 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Financial Stress 1 Esophageal Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 29 Carboplatin 20 durvalumab 19 Specimen Handling 19 Pemetrexed 17 Magnetic Resonance Spectroscopy 14 Cisplatin 14 osimertinib 12 atezolizumab 12 Paclitaxel 12 Nivolumab 12 Radiosurgery 10 Docetaxel 10 Gemcitabine 8 Radiation 7 Immunoglobulin G 7 Disulfides 7 Biopsy 7 Taxes 6 Radiotherapy 6 Platinum 6 Etoposide 6 Standard of Care 5 Ipilimumab 5 Cyclophosphamide 5 Bevacizumab 5 1,2-diaminocyclohexaneplatinum II citrate 5 fludarabine 4 brigatinib 4 Surveys and Questionnaires 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02247453 2024-03-07

BIOMILD

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Active not recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡